Clinical Commander

Back to dossier
uro.recurrent-uti-prophylaxis.v1PRODUCTION
uro.recurrent-uti-prophylaxis.v1

Recurrent UTI Prophylaxis & Long-term Management (adult women + postmenopausal + breakthrough)

urologychronicadultgeriatric
Hard-required inputs
0 / 16
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Adult woman with recurrent UTI (≥2/6mo or ≥3/12mo culture-confirmed) → prophylaxis pathway. Pivot: chronic indwelling catheter → uro.cauti.v1; pediatric → uro.uti.pediatric.v1; men → uro.uti.complicated.v1 for obstruction / prostatitis workup; pregnancy → modified pathway (AUA/CUA/SUFU 2019)

Inputs
3
Actions
0
Advance rule
Set
Advance when

engine scope confirmed

Patient inputs (20)

Establish recurrent definition (≥2/6mo or ≥3/12mo culture-confirmed) and pattern (postcoital, sporadic, breakthrough) (AUA/CUA/SUFU 2019)

Postmenopausal age tier → topical vaginal estrogen first-line adjunct; geriatric → atypical presentation considerations

Postmenopausal women benefit from topical vaginal estrogen — modifies vaginal microbiome (AUA 2019 PMID 31042112)

Poorly controlled DM → emphysematous pyelo risk; glycemic optimisation reduces recurrence

SOT / hematologic malignancy / HIV / chronic steroid → broader empirics on breakthrough; ID consult

Recurrent UTI + structural anomaly → urology imaging eval (renal US / CT) (AUA 2019)

Recent exposure drives resistance pattern; avoid prior agent

AVOID TMP-SMX prophylaxis if local E. coli resistance >20% (IDSA 2010; AUA 2019)

Sulfa allergy, nitrofurantoin pulmonary intolerance, etc.

Engine scope is adult women; men with recurrent UTI route to uro.uti.complicated.v1 for obstruction / prostatitis workup

Pregnancy modifies prophylaxis: AVOID nitrofurantoin near term + sulfa near term + FQ throughout; treat ASB (USPSTF 2019)

Chronic indwelling catheter → route off to uro.cauti.v1; do NOT prophylax routinely (drives MDR + CDI)

UA on each acute episode + post-prophylaxis baseline (AUA 2019)

Culture-confirmed recurrence is the definition; not symptom-defined (AUA 2019)

Dose adjustment for renal-cleared prophylaxis agents — nitrofurantoin AVOID if CrCl <30; methenamine AVOID in renal / hepatic impairment

Anticoagulant + TMP-SMX → INR rise; methotrexate + sulfa toxicity; methenamine + sulfa precipitation; topical estrogen + breast Ca history

Imaging eval if recurrent + anatomic concern / breakthrough / unusual organism (AUA 2019)

Postcoital pattern → postcoital single-dose prophylaxis candidate (AUA 2019)

On continuous, postcoital, vaginal estrogen, methenamine, cranberry — drives next-step decision

Recent instrumentation / stent / nephrolithotomy → post-procedural recurrence pattern

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (10)

10 need judgement
  • informationalsevererecurrent_immunocompromised
    Recurrent UTI in SOT / hematologic malignancy / HIV with low CD4 / chronic high-dose steroid → ID consult + tailored prophylaxis; broader empirics on breakthrough (AUA 2019)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatepostcoital_recurrent_UTI_women_postcoital_prophylaxis_TMP_SMX
    Clear postcoital UTI pattern in women — postcoital TMP-SMX SS or nitrofurantoin 50–100 mg within 2 h post-coital (AUA/CUA/SUFU 2019 PMID 31042112)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderaterecurrent_after_menopause_topical_vaginal_estrogen
    Postmenopausal woman with recurrent UTI — topical vaginal estrogen first-line adjunct (estradiol cream 0.5 g intravaginal twice weekly OR ring / tablet) (AUA 2019; vaginal estrogen meta PMID 21176321)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderaterecurrent_with_anatomic_abnormality_imaging_eval
    Recurrent UTI + anatomic concern (stricture, neurogenic bladder, stones, prior surgery) → imaging eval (renal US / non-contrast CT) + urology referral (AUA 2019)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderaterecurrent_diabetic_postoperative
    Recurrent UTI in DM (especially poorly controlled) or post-urologic-procedure → glycemic optimisation + tailored prophylaxis; consider lower threshold for imaging (AUA 2019; EAU 2020)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateCYP_resistant_recurrent
    Recurrent UTI with prior culture-resistant E. coli OR healthcare exposure OR recent abx → AVOID empiric TMP-SMX prophylaxis if local resistance >20%; switch to nitrofurantoin / methenamine / vaginal estrogen (IDSA 2010; AUA 2019)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatepediatric_recurrent_VUR_grade_3_to_5
    Pediatric recurrent UTI with VUR grade III–V — routes OFF this engine to uro.uti.pediatric.v1 (RIVUR / PRIVENT prophylaxis paradigm; surgical option)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatechronic_indwelling_catheter
    Chronic indwelling catheter + recurrent UTI — routes OFF this engine to uro.cauti.v1; DO NOT use continuous prophylaxis (drives MDR + CDI; IDSA 2019 explicit) (IDSA 2019 PMID 20175247)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildmethenamine_hippurate_for_prophylaxis
    Patient prefers non-antimicrobial OR resistance concern → methenamine hippurate 1 g PO BID (ALTAR trial PMID 30413181; AUA 2019)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildcranberry_extract_low_quality_evidence
    Patient preference for cranberry — counsel about low-quality evidence (Cochrane PMID 34473789); acceptable as adjunct but NOT first-line (AUA 2019)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

This dossier does not reference any calculators.

Recommended regimen

Recurrent UTI prophylaxis — continuous low-dose + postcoital + self-start + vaginal estrogen + methenamine + cranberry + behavioural + experimental vaccines (AUA/CUA/SUFU 2019)
axis: recurrent_uti_prophylaxis_optionsstep 1 - STEP 1 — Continuous low-dose antibiotic prophylaxis × 6–12 mo trial then reassess (AUA 2019)
Selected step "STEP 1 — Continuous low-dose antibiotic prophylaxis × 6–12 mo trial then reassess (AUA 2019)" — Recurrent UTI ≥2/6mo or ≥3/12mo, no postcoital pattern, no contraindication to chronic abx
  • trimethoprim-sulfamethoxazole (continuous low-dose)
    first line
    sulfa_antibiotic
    40/200 mg (SS) PO qhs • PO • once daily at bedtime × 6–12 mo
    triggers: recurrent_uti_continuous_prophylaxis, local_resistance_lt_20pct, no_sulfa_allergy
    AUA 2019 first-line continuous prophylaxis if local resistance <20% and no sulfa allergy (PMID 31042112)
    rxcui 10831
  • nitrofurantoin (continuous low-dose)
    first line
    nitrofuran_antibiotic
    50–100 mg PO qhs • PO • once daily at bedtime × 6–12 mo
    triggers: recurrent_uti_continuous_prophylaxis, sulfa_contraindicated_or_local_resistance_ge_20pct, CrCl_ge_30
    AUA 2019 first-line alternative; monitor long-term for pulmonary fibrosis (rare) + LFTs; AVOID if CrCl <30
    rxcui 7454
  • cephalexin (continuous low-dose alternative)
    second line
    cephalosporin_1st_gen
    125–250 mg PO qhs • PO • once daily
    triggers: nitrofurantoin_and_TMP_SMX_contraindicated, pregnancy_compatible
    AUA 2019 alternative — limited evidence but acceptable when other options contraindicated
    rxcui 2231

outpatient playbook — drug actions (6)

  1. 1. nitrofurantoin (continuous low-dose)
    50–100 mg PO qhs × 6–12 mo • PO • once daily
    trigger: Continuous prophylaxis chosen; CrCl ≥30; no pulmonary contraindication
    AUA 2019 first-line continuous
  2. 2. TMP-SMX (continuous low-dose)
    40/200 mg (SS) PO qhs × 6–12 mo • PO • once daily
    trigger: Local resistance <20%; no sulfa allergy
    AUA 2019 first-line alternative
  3. 3. nitrofurantoin OR TMP-SMX (postcoital single dose)
    50–100 mg nitrofurantoin OR 40/200 mg TMP-SMX SS within 2 h postcoital • PO • postcoital single dose
    trigger: Honeymoon pattern; single-dose preference
    AUA 2019
  4. 4. estradiol (vaginal cream)
    0.5 g intravaginal twice weekly • topical_vaginal • twice weekly
    trigger: Postmenopausal recurrent UTI
    AUA 2019 first-line postmenopausal adjunct (PMID 21176321)
  5. 5. methenamine hippurate
    1 g PO BID • PO • BID
    trigger: Non-antimicrobial preference OR resistance concern
    AUA 2019; ALTAR trial (PMID 30413181)
  6. 6. nitrofurantoin OR fosfomycin (self-start)
    Nitro 100 mg PO BID × 5 d OR fos 3 g PO × 1 at symptom onset • PO • per agent
    trigger: Reliable patient + clear symptom recognition
    AUA 2019 self-start

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: ≥2 culture-confirmed UTI in 6 mo OR ≥3 in 12 mo (AUA/CUA/SUFU 2019 definition); Recurrent UTI within days of intercourse — honeymoon pattern; postcoital prophylaxis candidate; Postmenopausal woman with recurrent UTI → topical vaginal estrogen first-line adjunct.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Recurrent UTI Prophylaxis & Long-term Management (adult women + postmenopausal + breakthrough)** (uro.recurrent-uti-prophylaxis.v1).
Phenotype framing: Recurrent UTI vs interstitial cystitis vs pelvic floor dysfunction vs vulvovaginitis vs urethritis (STI) vs anatomic anomaly vs chronic prostatitis (men) vs interstitial cystitis (AUA 2019)
Scope: Adult woman with recurrent UTI (≥2/6mo or ≥3/12mo culture-confirmed) → prophylaxis pathway. Pivot: chronic indwelling catheter → uro.cauti.v1; pediatric → uro.uti.pediatric.v1; men → uro.uti.complicated.v1 for obstruction / prostatitis workup; pregnancy → modified pathway (AUA/CUA/SUFU 2019)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Recurrent UTI prophylaxis — continuous low-dose + postcoital + self-start + vaginal estrogen + methenamine + cranberry + behavioural + experimental vaccines (AUA/CUA/SUFU 2019)** — step "STEP 1 — Continuous low-dose antibiotic prophylaxis × 6–12 mo trial then reassess (AUA 2019)".
1. trimethoprim-sulfamethoxazole (continuous low-dose) 40/200 mg (SS) PO qhs PO once daily at bedtime × 6–12 mo (sulfa_antibiotic, first line) — AUA 2019 first-line continuous prophylaxis if local resistance <20% and no sulfa allergy (PMID 31042112)
2. nitrofurantoin (continuous low-dose) 50–100 mg PO qhs PO once daily at bedtime × 6–12 mo (nitrofuran_antibiotic, first line) — AUA 2019 first-line alternative; monitor long-term for pulmonary fibrosis (rare) + LFTs; AVOID if CrCl <30
3. cephalexin (continuous low-dose alternative) 125–250 mg PO qhs PO once daily (cephalosporin_1st_gen, second line) — AUA 2019 alternative — limited evidence but acceptable when other options contraindicated

Setting playbook (outpatient) — Primary prophylaxis selection + annual reassessment — confirm recurrent UTI definition (≥2/6mo or ≥3/12mo culture-confirmed); select agent per pattern (postcoital → postcoital single dose; sporadic → continuous low-dose; postmenopausal → vaginal estrogen first-line adjunct; non-abx preference → methenamine); urology referral if breakthrough / anatomic / unusual organism; behavioural counsel always (AUA/CUA/SUFU 2019)
4. nitrofurantoin (continuous low-dose) 50–100 mg PO qhs × 6–12 mo PO once daily — Continuous prophylaxis chosen; CrCl ≥30; no pulmonary contraindication (AUA 2019 first-line continuous)
5. TMP-SMX (continuous low-dose) 40/200 mg (SS) PO qhs × 6–12 mo PO once daily — Local resistance <20%; no sulfa allergy (AUA 2019 first-line alternative)
6. nitrofurantoin OR TMP-SMX (postcoital single dose) 50–100 mg nitrofurantoin OR 40/200 mg TMP-SMX SS within 2 h postcoital PO postcoital single dose — Honeymoon pattern; single-dose preference (AUA 2019)
7. estradiol (vaginal cream) 0.5 g intravaginal twice weekly topical_vaginal twice weekly — Postmenopausal recurrent UTI (AUA 2019 first-line postmenopausal adjunct (PMID 21176321))
8. methenamine hippurate 1 g PO BID PO BID — Non-antimicrobial preference OR resistance concern (AUA 2019; ALTAR trial (PMID 30413181))
9. nitrofurantoin OR fosfomycin (self-start) Nitro 100 mg PO BID × 5 d OR fos 3 g PO × 1 at symptom onset PO per agent — Reliable patient + clear symptom recognition (AUA 2019 self-start)

Non-pharmacologic actions:
- Patient education — distinguish acute episode (treat per uro.uti.uncomplicated.v1) from prophylaxis (this engine)
- Symptom diary; clinic visits for annual reassessment
- Behavioural counsel — hydration, postcoital voiding, hygiene, avoid spermicide/diaphragm
- Cranberry products optional — counsel low-quality evidence
- Urology referral if breakthrough / anatomic / unusual organism / hematuria persistent
- Postmenopausal vaginal estrogen — discuss breast cancer history before prescribing

AVOID / contraindication checks:
- TMP_SMX_AVOID_prophylaxis_if_local_E_coli_resistance_gt_20pct (IDSA 2010 / AUA 2019)
- TMP_SMX_AVOID_near_term_pregnancy_kernicterus (USPSTF 2019)
- TMP_SMX_interaction_with_warfarin_INR_rise (FDA)
- TMP_SMX_interaction_with_methotrexate_toxicity (FDA)
- Nitrofurantoin_AVOID_if_CrCl_lt_30 (FDA / IDSA)
- Nitrofurantoin_AVOID_in_pyelonephritis_no_renal_tissue_penetration (IDSA)
- Nitrofurantoin_long_term_pulmonary_fibrosis_LFTs_monitor (FDA)
- Nitrofurantoin_AVOID_near_term_pregnancy_G6PD_neonatal_hemolysis (USPSTF)
- Fluoroquinolones_AVOID_for_prophylaxis_FDA_Black_Box_collateral_damage (FDA 2016)
- Methenamine_AVOID_in_renal_or_hepatic_impairment (FDA / AUA 2019)
- Methenamine_AVOID_with_sulfa_precipitation_of_sulfa_in_acid_urine (FDA)
- Topical_vaginal_estrogen_breast_ca_history_use_after_oncologist_consult (AUA 2019)
- Continuous_antibiotic_prophylaxis_in_chronic_indwelling_catheter_AVOID_drives_MDR_route_to_cauti (IDSA 2019)
- Asymptomatic_bacteriuria_DO_NOT_TREAT_except_pregnancy_or_pre_procedure (USPSTF / IDSA 2019)
- Annual_reassessment_of_continuous_prophylaxis_mandatory (AUA 2019)
- Cranberry_low_quality_evidence_counsel_before_recommending_Cochrane (Cochrane / AUA 2019)

Monitoring

Regimen monitoring:
- symptom diary and culture each acute episode (AUA 2019)
- annual reassessment of continuous prophylaxis trial off after 6 to 12mo (AUA 2019)
- long term nitrofurantoin pulmonary review and LFTs (FDA)
- breakthrough uti consider switch agent and urology referral (AUA 2019)
- resistance surveillance via culture on each episode (AUA 2019)
- postmenopausal vaginal estrogen ongoing review (AUA 2019)
- methenamine adherence and LFTs during extended use (FDA)
- renal function q6 12mo during continuous prophylaxis (IDSA)
- reassess lifestyle factors annually (AUA 2019)

Setting (outpatient) monitoring:
- Annual reassessment of continuous prophylaxis (AUA 2019)
- Trial off after 6–12 mo of symptom-free continuous prophylaxis
- Long-term nitrofurantoin — annual pulmonary review + LFTs (FDA)
- Resistance surveillance — culture each acute episode (AUA 2019)

Follow-up plan: Annual reassessment of continuous prophylaxis; trial off after 6–12 mo; urology referral if breakthrough; postmenopausal vaginal estrogen ongoing; methenamine adherence; behavioural reinforcement (AUA 2019)
- Close-out criterion: follow-up + reassessment cadence documented

Monitoring phase: Symptom diary; culture each acute episode; annual reassessment of prophylaxis; resistance surveillance; LFTs / pulmonary review for long-term nitrofurantoin; QTc / LFTs for fluconazole if used (AUA 2019)

Disposition

Current setting: outpatient — Primary prophylaxis selection + annual reassessment — confirm recurrent UTI definition (≥2/6mo or ≥3/12mo culture-confirmed); select agent per pattern (postcoital → postcoital single dose; sporadic → continuous low-dose; postmenopausal → vaginal estrogen first-line adjunct; non-abx preference → methenamine); urology referral if breakthrough / anatomic / unusual organism; behavioural counsel always (AUA/CUA/SUFU 2019)

Disposition criteria:
- Outpatient PCP / urology primary; ED for acute breakthrough with sepsis features
- Annual reassessment visit scheduled

Escalation triggers (move to higher acuity):
- Breakthrough on prophylaxis → switch agent + urology referral (AUA 2019)
- Fever / flank pain → ED (route to acute pyelo pathway)
- Unusual organism (Proteus, ESBL) → ID consult + imaging eval
- Pregnancy + recurrent → modified regimen + OB co-management

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [SEVERE] Recurrent UTI in SOT / hematologic malignancy / HIV with low CD4 / chronic high-dose steroid → ID consult + tailored prophylaxis; broader empirics on breakthrough (AUA 2019)
- [MODERATE] Clear postcoital UTI pattern in women — postcoital TMP-SMX SS or nitrofurantoin 50–100 mg within 2 h post-coital (AUA/CUA/SUFU 2019 PMID 31042112)
- [MODERATE] Postmenopausal woman with recurrent UTI — topical vaginal estrogen first-line adjunct (estradiol cream 0.5 g intravaginal twice weekly OR ring / tablet) (AUA 2019; vaginal estrogen meta PMID 21176321)

Citations

- AUA/CUA/SUFU Recurrent uncomplicated UTI in Women 2019 (Anger) + IDSA Acute Uncomplicated Cystitis/Pyelonephritis 2011 (Gupta) + cranberry meta-analysis 2021 + ALTAR methenamine non-inferiority trial + SOGC Recurrent UTI guideline (vaginal estrogen + cranberry) [PMID:21292654](https://pubmed.ncbi.nlm.nih.gov/21292654/)
- Cited evidence (PMID 31042112) [PMID:31042112](https://pubmed.ncbi.nlm.nih.gov/31042112/)
- Cited evidence (PMID 34473789) [PMID:34473789](https://pubmed.ncbi.nlm.nih.gov/34473789/)
- Cited evidence (PMID 30413181) [PMID:30413181](https://pubmed.ncbi.nlm.nih.gov/30413181/)
- Cited evidence (PMID 21176321) [PMID:21176321](https://pubmed.ncbi.nlm.nih.gov/21176321/)

Last reconciled with current guidelines: 2026-05-22.
References
  • AUA/CUA/SUFU Recurrent uncomplicated UTI in Women 2019 (Anger) + IDSA Acute Uncomplicated Cystitis/Pyelonephritis 2011 (Gupta) + cranberry meta-analysis 2021 + ALTAR methenamine non-inferiority trial + SOGC Recurrent UTI guideline (vaginal estrogen + cranberry) — PMID:21292654
  • Cited evidence (PMID 31042112) — PMID:31042112
  • Cited evidence (PMID 34473789) — PMID:34473789
  • Cited evidence (PMID 30413181) — PMID:30413181
  • Cited evidence (PMID 21176321) — PMID:21176321